2023
Inflamed but not impulsive: Acute inflammatory cytokine response does not impact prepotent response inhibition
Madison A, Andridge R, Renna M, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, Williams N, Sardesai S, Noonan A, Reinbolt R, Cherian M, Malarkey W, Kiecolt-Glaser J. Inflamed but not impulsive: Acute inflammatory cytokine response does not impact prepotent response inhibition. Journal Of Affective Disorders 2023, 342: 1-9. PMID: 37683942, PMCID: PMC10591975, DOI: 10.1016/j.jad.2023.09.008.Peer-Reviewed Original ResearchConceptsInflammatory cytokine responseCytokine responsesCancer survivorsTyphoid vaccineConners' Continuous Performance TestPostmenopausal breast cancer survivorsInterleukin-1 receptor antagonistResponse inhibitionBreast cancer survivorsInterleukin-6 responseSaline placebo injectionsOutcomes of interestPolysaccharide vaccinationPlacebo injectionsCrossover trialReceptor antagonistSeparate visitsContinuous Performance TestSecondary analysisAspects of impulsivityPlaceboNon-significant resultsPrepotent response inhibitionVaccineInjection
2022
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy